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What this paper adds:  48 
Placebo controlled trials of cell therapy to reduce major amputations in patients with critical 49 
limb ischemia and no-option for revascularization have so far not been successful.  PLX-PAD 50 
cell treatment (placenta derived adherent stromal cells)  has in small studies shown 51 
promising results, and the phase III PACE trial is designed to evaluate the efficacy and safety 52 
of two sessions of intramuscular injections, 8 weeks apart in follow up  of 12-36 months. 53 
Thus, the study will provide long term outcome and will collect  parameters to assess 54 
potential ecomomic benefit for this kind of treatment.  55 
 56 
Abstract 57 
Background: Critical limb ischemia (CLI) is a life threatening condition with a considerable 58 
risk for death and major amputation.  Besides revascularization, no treatment has been 59 
proven to reduce the risks. Therapeutic angiogenesis by gene or cell therapy has not 60 
demonstrated definitive evidence in randomized controlled trials. PLX-PAD is an ‘off-the-61 
shelf’ allogeneic placental derived, mesenchymal-like cell therapy that in preclinical studies 62 
has shown  pro-angiogenic, anti-inflammatory and regenerative properties. Favorable 1-year 63 
amputation free survival (AFS), and trends in reduction of pain scores and in increase of 64 
tissue perfusion have been shown in two small, open-label, phase I trials. 65 
 66 
Study design: The PACE study is a phase III randomized, double-blind, multicenter, 67 
multinational placebo-controlled, parallel-group study to evaluate the efficacy, tolerability 68 
and safety of intramuscular injections of PLX-PAD cells to treat patients with atherosclerotic 69 
CLI with minor tissue loss (Rutherford Category 5) up to the ankle level, who are unsuitable 70 
for revascularization or carry an unfavorable risk-benefit for that treatment. The study will 71 
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enroll 246 patients, who after screening are randomized in a ratio of 2:1 to treatment with 72 
intramuscular injections of PLX-PAD 300X106 cells or placebo at two occasions, 8 weeks 73 
apart. The primary efficacy endpoint is time to major amputation or death (amputation free 74 
survival), which will be assessed in follow-up of after at least 12 months and up to 36 75 
months.  76 
 77 
Conclusions: Based on favorable pre-clinical and initial clinical study results, the PACE phase 78 
III randomized controlled trial will evaluate placenta-derived PLX-PAD cell treatment in  79 
patients with critical limb ischemia, carrying an unfavorable risk-benefit for 80 
revascularization.  81 
 82 
Abstract word count: 255 83 
 84 














Critical limb ischemia (CLI) constitutes the most advanced stage of chronic peripheral arterial 97 
disease (PAD) and includes rest pain and ischemic foot lesions. The condition affects 1-5 % of 98 
all PAD patients, which corresponds to an incidence of 500-1000 / million population per 99 
year (1). Overall, the prevalence of PAD increases worldwide, most remarkably in low- and 100 
middle income countries (2). Major amputation and death are the ultimate consequences of 101 
CLI, and a 1-year amputation rate of 15-25% is commonly reported, while amputation & 102 
mortality rate ranges 30-40%. The single evidence-based recommendation for treatment is 103 
revascularization (1,3,4). Due to co-morbidities with greater risk to perform an 104 
interventional procedure, or based on anatomical or technical issues, a proportion of CLI 105 
patients is not reasonable to revascularize or to re-revascularize after a failed procedure. 106 
Few treatments exist for such “poor-option” cases. Prostanoid therapy has been reasonably 107 
well studied in randomized controlled trials, but does not carry evident effect, and is not 108 
recommended in present guidelines (1,3). Since about 20 years, therapeutic angiogenesis 109 
has been studied, based on either gene or cell therapy. 110 
 111 
Gene therapy 112 
Gene therapy utilizing growth factors, Vascular Endothelial Growth Factor (VEGF), Fibroblast 113 
Growth Factor (FGF) and Hepatocyte Growth Factor (HGF), has been investigated in mostly 114 
smaller clinical trials, with varying success with regard to the major efficacy endpoint, 115 
amputation-free survival (AFS). Only NV1FGF has been investigated in a larger randomized 116 
placebo controlled trial, TAMARIS (5) that did not show any better outcome regarding 117 
survival or major amputation in the treatment group compared to placebo, despite the fact 118 
that a former, smaller trial, TALISMAN (6), showed that major amputation, as a secondary 119 
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endpoint, was significantly less frequent among NV1FGF treated subjects. Injections of the 120 
HGF plasmid have yet to prove efficacy with regard to major events, though smaller 121 
randomized placebo controlled trials have shown reduced rest pain (7) and increased toe 122 
brachial index (TBI)  (8) at follow up. More has to be learnt both from basic and clinical 123 
research to possibly adopt effective gene therapy for PAD (9), though Iver and Annex (10) 124 
discuss a conceivable end of gene therapy trials, based on the lack of an evident break-125 
through.   126 
 127 
Cell therapy 128 
The potential benefit of cell therapy is that cell secretion is multifactorial and therefore not 129 
based solely on a single growth factor.  Initiated by a Japanese study (11) comparing bone-130 
marrow- and peripheral blood mononuclear cells (PBMC) injected into the limb muscles of 131 
patients with PAD, several cell-based studies have been performed, specifically in CLI 132 
patients with no option for revascularization. The Japanese study (11) showed improved 133 
ankle-brachial index (ABI) and transcutaneous tissue oxygen pressure (TcPO2) and reduced 134 
rest pain in the bone-marrow mononuclear cell treated group.  Though the majority of 135 
studies have utilized intramuscular injections of the growth factor, the largest trial, Juventas, 136 
treated 160 patients with intra-arterial infusions of bone-marrow mononuclear cells (BM-137 
MNC) compared to placebo (12). At 6 months there was no difference in the rate of major 138 
amputations. 139 
In a meta-analysis by Teraa et al (13), including 12 randomized controlled trials (RCT) in 140 
autologous cell therapy for CLI, major amputations were significantly reduced. Most 141 
importantly, when only placebo controlled RCTs were included, the major amputations were 142 
no longer significantly reduced, indicating the importance of placebo controlled trials in cell 143 
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therapy. In a later meta-analysis by the same author group (14) only including placebo-144 
controlled RCTs, this outcome was verified. Recently this finding was also verified in another 145 
meta-analysis on CD34+ mononuclear cell therapy (CD34+MCT), including 10 trials (15). Total 146 
amputations and ulcer healing were reduced in comparison with findings in the placebo 147 
treated groups. Major amputation and survival were, however, not significantly reduced. 148 
This publication also concluded the beneficial value of a high CD34+ cell content. 149 
 150 
Autologous or allogeneic cell utilization 151 
From an immunological point of view, autologous cell treatment may theoretically provide 152 
an immunological advantage.  Nevertheless, it has been shown that cells harvested from 153 
older individuals, and in particular those with cardiovascular risk factors or critical limb 154 
ischemia, are reduced in number and functionality (16, 17).  Furthermore, harvesting 155 
autologous cells from bone marrow involves an invasive procedure, while peripheral blood 156 
utilization requires granulocyte colony stimulation factor (G-CSF) treatment that potentially 157 
may cause harm due to the high white blood cell content that is developed (18). Allogeneic 158 
MSCs have been shown to exhibit low immunogenicity (19), thus, utilizing allogeneic 159 
younger, more potent cells, rather than treatment with cells harvested from the diseased 160 
patients themselves, therefore should be of benefit. In this respect PLX-PAD cells from young 161 
healthy placental tissue have the potential for higher efficacy than previously seen with 162 
autologous cell products. 163 
 164 
PLX-PAD:  Allogeneic Cell Therapy   165 
PLX-PAD is a cell therapy product, composed of placental expanded adherent stromal cells. 166 
While PLX-PAD cells exhibit membrane marker expression typical of classical mesenchymal 167 
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stromal cells (20), they have a minimal ability to differentiate in vitro into cells of 168 
mesodermal lineage. Therefore, their proposed mechanism of action is a timely secretion of 169 
various proteins which induce angiogenesis,  immunomodulatory activities, and promotion 170 
of regeneration of muscle tissue. 171 
Angiogenesis, the formation of new vessels, is induced by a variety of factors released from 172 
ischemic tissues, and is a critical physiological mechanism for alleviation of PAD or for 173 
recovery of muscle tissue functionality after injury. The angiogenic process involves 174 
migration of endothelial progenitors and pericytes towards the site of interest. In vitro 175 
studies have shown the capacity of PLX-PAD cells to promote endothelial cell proliferation 176 
(20). The cells secrete pro-angiogenic proteins including VEGF, angiopoietin-1, osteopontin, 177 
MMP-1, MMP-2, HGF and angiogenin, all of which are up-regulated under hypoxic culture 178 
conditions (20, 21 and unpublished data). Angiogenin further interacts with endothelial and 179 
smooth muscle cells, resulting in cell migration, invasion, proliferation and formation of 180 
tubular structures (22). (Fig 1, Table 1).  181 
PAD is associated with an inflammatory process that leads to tissue damage and precludes 182 
active repair. Oxidative stress  due to endothelial dysfunction is evident in PAD and leads to 183 
persistent inflammation. Proinflammatory cytokines, e.g. TNF-α, IL-6 , IL-1β , play a key role 184 
in the inflammatory process, and PLX-PAD cells mitigate this process by releasing anti-185 
inflammatory and immunomodulating cytokines (i.e. GDF-15, CXCL12,TGF-β).  Following 186 
exposure to pro-inflammatory cytokines (such as TNF-α and IFN-γ) PLX-PAD cells further 187 
upregulate some of the anti-inflammatory secretions (i.e. IDO, PD-L1, HGF, IL-11, CCL5). 188 
Furthermore, when cultured with activated PBMCs, PLX-PAD induce upregulation of PBMC 189 
secreted anti-inflammatory cytokines such as IL-10, and IL-1RA), also indirectly affecting 190 
endothelial dysfunction and protecting endothelial cell viability (20 and unpublished data).  191 
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As ischemic conditions lead to muscle degeneration, muscle regeneration is of potential 192 
therapeutic benefit in PAD. PLX-PAD cells have been shown to promote migration of skeletal 193 
muscle cells in vitro and improve muscle function and accelerate muscle regeneration in vivo 194 
(manuscript in preparation).    195 
To summarize, PLX-PAD cells secrete proteins that are known to be involved in promoting 196 
angiogenesis, downregulating inflammation and inducing regeneration of muscle tissue. 197 
 198 
 In vivo, in the mouse hind limb ischemia (HLI) model in which the femoral artery of one 199 
hindlimb is cut and ligated thus inducing complete ischemia in the operated limb, (21, 23), 200 
 PLX-PAD cells have been shown to restore blood flow to the ischemic limb . Furthermore, it 201 
 was shown that PLX-PAD cells exert a systemic effect, since injection of the cells to the 202 
 contralateral limb exerted an almost similar restoration of blood flow, but required a larger 203 
 dose of cells. A second administered dose of  PLX-PAD cells 21 days after the first dose 204 
 afforded additional efficacy in re-establishing blood flow in case the effect was declining (Fig 205 
 2).  This study and others have also shown that PLX-PAD cells injected intramuscularly do 206 
 not migrate from the injection site to other tissues and do not differentiate in culture, 207 
 further supporting the suggested mode of action of PLX-PAD cells through secretion of 208 
 proteins.  209 
 210 
Clinical studies in PAD 211 
Two phase I open-label, dose escalation studies were conducted to assess the safety of 212 
intramuscular injections of PLX-PAD cells in 27 CLI subjects (Rutherford Categories 4 and 5), 213 
who were not candidates for revascularization.  214 
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Study 1202-1 was conducted in Germany and assessed three single doses of 175 million cells 215 
(low dose, n=3), 315 million cells (intermediate dose, n=6) and 595 million cells (high dose, 216 
n=6). Study 1202-2 was conducted in the United States (US) and assessed a single versus 2 217 
doses (2 weeks apart) of 280 million cells, the first group included 7 patients,  the latter 218 
included 5 patients. PLX-PAD cells were administered intramuscularly into the affected leg 219 
via 30 to 50 injections.  220 
Overall, the safety of this process in CLI subjects was found to be acceptable, and it was 221 
confirmed that HLA–matching is not required. Adverse events included mostly injection-sites 222 
reactions such as pain, muscle contractions/fasciculations, pruritus, hematoma, etc. (mostly 223 
transient and of mild/moderate intensity), transient allergic reactions, and bad breath due to 224 
the DMSO (dimethyl sulfoxide) content. 225 
These phase I studies were not powered to demonstrate clinical efficacy, however, some 226 
parameters have indicated a positive clinical effect. The pooled amputation free survival rate 227 
at 6 months and 1 year across the two studies was 96% and  85% respectively, which is 228 
higher than the rates described in similar patient populations (24, 25). Pain scores, as 229 
assessed by the Visual Analog Scale (VAS), showed a trend of decrease after treatment with 230 
PLX-PAD in all dose groups, up to a decrease of 2.5 units in the patients treated at the dose 231 
of 315 million cells. TcPO2, which is considered an indicator of tissue perfusion, 232 
demonstrated a trend of increase over time in all study groups with the greatest increase of 233 
up to 15 mmHg in the repeated-dose group (Fig 3). (data on file) 234 
In summary, based on the pro-angiogenic, immunomodulatory, and muscle regeneration 235 
capacities of PLX-PAD, as well as the results from animal experiments and outcome of the 236 




PACE trial design 239 
The PACE study (A randomized, double-blind, multicenter, placebo-controlled, parallel-group 240 
Phase III study to evaluate the efficacy, tolerability and safety of intramuscular injections of 241 
PLX-PAD for the treatment of subjects with critical limb ischemia (CLI) with minor tissue loss 242 
who are unsuitable for revascularization) was designed to investigate time to major 243 
amputation or death  (AFS) after up to 36 months. The study is planned to enroll a total of 244 
246 patients with minor foot lesions (Rutherford Category 5) up to the ankle level. Patients 245 
should be unsuitable for revascularization or carry an unfavorable risk- benefit to 246 
revascularization. Ineligibility for revascularization is determined by either severe co-247 
morbidity, anatomical or technical challenges (e.g. lack of vein for a bypass or inadequate 248 
target vessels for an endovascular procedure) or failed revascularization procedures with 249 
persistence of CLI after the procedure. Only patients with atherosclerotic disease are 250 
included, those with thrombangitis obliterans (Buerger´s disease) are excluded. Table 2 251 
shows the main inclusion and exclusion criteria. 252 
Subjects are screened up to 5 weeks before randomization. If found eligible, patients are 253 
randomized in a ratio of 2:1 to treatment with PLX-PAD 300x106 cells or with placebo. 254 
Treatment is administered at two time points, 8 weeks apart. At each occasion, thirty 255 
intramuscular injections, 0.5 mL each, are administered in the index leg along its length, 256 
anteriorly and posteriorly, according to a standard injection-sites scheme. A strict procedure 257 
is applied for cell preparation and administration in order to maintain study blinding. Dosage 258 
and timing of injections are based on preclinical and accumulated clinical data. 259 
Each subject will be followed-up for at least 12 months post randomization or until the 12 260 
months visit of the last patient randomized. Maximal follow up allowed by protocol is 36 261 
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months post randomization, hence all subjects will be followed-up for 12-36 months. The 262 
study design is presented in Fig. 4.  263 
The primary efficacy endpoint of the study is time-to occurrence of major amputation or 264 
death, i.e. amputation-free survival up to 36 months after randomization. Safety and 265 
tolerability are to be evaluated as well as other secondary and exploratory endpoints (Table 266 
3). The study will also assess a potential economic benefit of this regenerative treatment 267 
approach by applying a health-economic evaluation, taking into account relevant parameters 268 
as days of hospitalization and patient reported quality of life. 269 
The study will be performed in 50 sites in Europe and the USA 270 
 271 
Statistical considerations 272 
The sample size of 246 subjects provides a power of 89.7%, and is based on the 2:1 ratio 273 
randomization to treatment, an estimated AFS of 65% in the placebo group at the end of the 274 
first year, and a risk reduction of approximately 50%  for the PLX-PAD group  during the first 275 
year, using the the log-rank test. The primary endpoint will be analyzed using the Cox 276 
Proportional Hazards model. The study randomization is stratified for the presence of 277 
diabetes mellitus, for the extent of ischemic lesions, and for geographical region, which will 278 
be covariates in the statistical model.  279 
 280 
Discussion 281 
Although critical limb ischemia affects a small proportion of patients with PAD, and an 282 
increasing part of them are offered revascularization (26), other treatments are required for  283 
some patients in order to possibly increase survival and reduce major amputations. The fact  284 
that trials have had problems with slow recruitment of no-option patients, e.g. the TAMARIS  285 
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trial (5) and the AGILITY HGF trial, that had to be canceled for that reason (10) might be  286 
interpreted in a way that few patients do require alternative treatments. However, in 287 
addition to no-option cases, revascularizations may fail or only partly reduce CLI symptoms, 288 
and poor option subjects for revascularization  due to co-morbidity or for technical reasons 289 
will still be a reality. In a recent paper, Martinez et al (27) discussed predictive factors of 290 
poor short-term outcome (mortality and major amputation) following revascularization, 291 
including age, low hemoglobin values, acute myocardial infarction, ischemic ulcers and 292 
infrapopliteal revascularization. For such groups of fragile CLI patients, therapeutic 293 
angiogenesis may be an alternative.  294 
As larger gene therapy trials have failed, although there is still an interest in the evaluation 295 
of  HGF (9), and doubts exist with regard to cell therapy (14,15),  no such treatment has yet 296 
been approved for clinical use. It could be interpreted that single growth factor trials may 297 
not be able to provide the complete array of factors that the patients in this population 298 
require.  Therefore, precursor cell therapy would  potentially provide a more complete array 299 
of factors.  It is reasonable to assume that the age and condition of cells, harvested from the 300 
potential patients, are crucial. It has been shown that CLI patients produce lower levels of 301 
progenitor cells (17) and an increasing cardiovascular risk is also related to a lower number 302 
of progenitor cells (16). In addition, cells harvested and injected at the point of service, are 303 
not by their nature able to be characterized nor quantified before being injected, therefore 304 
bringing into question their very nature.  Furthermore, it has been shown that growth of 305 
isolated mesenchymal stem cells  is significantly related to the age of the donor (28), and 306 
thus young allogeneic placental cells may be most relevant for the purpose of treatment as 307 
they come from a young healthy donor.   308 
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Most importantly, PLX-PAD cells, being of a placental source, known for its immune-309 
priviledged characteristics, have been shown to not exert an immunological effect neither in 310 
vitro nor in vivo in animal models and humans, requiring no immunesupression prior to PLX-311 
PAD administration (29). 312 
The PACE trial only includes patients with ischemic lesions and does not enroll Rutherford 313 
Category 4 cases with just rest pain, due to the inobjectivity of evaluating pain. In practice, 314 
CLI patients with rest pain may also be those who most frequently will be offered 315 
revascularization. Hence, pain is not included in the composite primary efficacy endpoint in 316 
Rutherford Category 5 patients. Furthermore, these patients are at higher risk of major 317 
amputation, thus providing the best evidence on the effect on AFS. 318 
The trial design takes into account the greater efficacy of two cell administrations rather 319 
than one as shown in both animal models and human subjects, and therefore a second 320 
administration session is given two months after the first session. Some patients will be 321 
followed up to 36 months, which will enable collection of highly important information on 322 
long-term effects of the treatment. and will also increase knowledge on the natural course 323 
of severe CLI . The primary efficacy endpoint, amputation free survival is selected as the 324 
strictest endpoint to be evaluated. Disease progression, wound healing, ischemic pain, 325 
quality of life, TcPO2, ABI/TBI measures and hospitalization days data are included as 326 
secondary and exploratory endpoints. 327 
The term therapeutic angiogenesis may be interpreted as the mode of action by which new 328 
vessels are formed, thus potentially increasing perfusion. In human studies, however, 329 
present imaging technology is only occasionally able to show newly developed vessels 330 
despite the fact that subjects may be improved. It is evident that other pathophysiological 331 
events are affected as well, primarily the inflammatory process. PLX-PAD cells exert effects 332 
14 
 
on both angiogenesis and tissue inflammation, but also on regeneration of muscle cells. 333 
Whether the latter is a mechanism of value for improvement of function and symptoms in 334 
CLI patients should be further investigated.   335 
In summary, cell therapy works in a multifactorial way,  PLX-PAD cells are young and potent, 336 
they secrete relevant factors, are easily accessible in required quantity without harvesting 337 
from fragile patients putting those at additional risk and have shown pre-clinical and initial 338 
clinical evidence of efficacy. The design of the PACE trial, including only patients with 339 
ischemic foot lesions, dual injections along the whole limb, follow-up up to 36 months, and 340 
with a primary efficacy endpoint based on long term time-to-event regarding amputation-341 
free survival may allow for better understanding of perfusion enhancement and change of 342 
inflammatory response and improved outcome for patients with severe critical limb 343 
ischemia. 344 
  345 
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Table 1 619 
Cytokines secreted by PLX-PAD and their function 620 
 621 
Angiogenesis   VEGF (Vascular Endothelial Growth Factor) 622 
Angiogenin 623 
    Angiopoietin 1 624 
    HGF (Hepatocyte Growth Factor) 625 
                                                                        Osteopontin 626 
                                                                        MMP-1 (matrix metalloproteinase 1) 627 
                                                                        MMP-2 628 
Immunomodulation  Osteopontin 629 
    CXCL12 /SDF 1 (Stromal Cell-derived Factor 1) 630 
    GDF 15 (Growth Differentiation Factor 15) 631 
    MIF (Macrophage Migration Inhibition Factor) 632 
                                                                        IDO (Indoleamine 2,3-dioxygenase) 633 
                                                                        TGF-β (Transforming growth factor beta) 634 
                                                                        PD-L1 (Programmed death ligand 1) 635 
                                                                        HGF 636 
                                                                        IL-11 (Interleukin 11) 637 
                               CCL5 (RANTES- regulated on activation, normal T cell 638 
 expressed and secreted) 639 
                                                                              640 
Muscle regeneration  Decorin 641 
    MMP 1  642 
    HGF 643 
    TGF  β  644 
    Galectin 1                                                                                   645 
    IGFBP-3 (Insulin growth factor binding protein 3) 646 
    FLRG (FSTL3- Follistatin-related protein 3) 647 
    Osteopontin 648 
    CXCL12 /SDF 1  649 
 650 







Table 2 656 
 657 
Main inclusion criteria: 658 
• Age 45-99 years. 659 
• CLI due to atherosclerosis with minor tissue loss (Rutherford 5) up to the ankle level. 660 
• Ankle pressure  ≤70 mmHg or toe pressure ≤50 mmHg. 661 
• Subject unsuitable for revascularization (by any method) in the index leg, based on 662 
unfavorable risk-benefit assessment. 663 
• Ischemic lesions neither healing, nor significantly worsening (within 2 weeks during 664 
screening)  665 
• Ischemic lesions without tendon or bone exposure (unless secondary to a minor 666 
amputation). 667 
 668 
Main Exclusion criteria: 669 
• Non-atherosclerotic PAD (e.g. Buerger's disease). 670 
• CLI with major tissue loss (Rutherford Category 6) in either leg. 671 
• Evidence of active infection (e.g., cellulitis, osteomyelitis). 672 
• Subject having undergone surgical revascularization <1 month prior to study, or 673 
endovascular revascularization/minor amputation <2 weeks prior. 674 
• Planned or potential need for major/minor amputation or revascularization within 1 month 675 
of study entry. 676 
• Aorto-iliac stenosis or common femoral artery stenosis ≥70%. 677 
• Use of hyperbaric oxygen therapy, prostanoids, spinal cord stimulation, lumbar 678 
sympathectomy, wound dressing containing cells or growth factors, or topical platelet 679 
derived growth factor. 680 
• Stroke or acute myocardial infarction/unstable angina within 3 months prior to screening. 681 
• Severe congestive heart failure symptoms (New York Heart Association [NYHA] Stage 682 
IV). 683 
• Uncontrolled severe hypertension. 684 
• Diabetes mellitus with HbA1c >10%. 685 
• Subject on renal replacement therapy or with eGFR <15 mL/min/1.73m2. 686 
• Pulmonary disease requiring supplemental oxygen treatment on a daily basis. 687 

















Table 3 703 
Primary Efficacy Endpoint: 704 
• Time to occurrence of major amputation or death (amputation-free survival). 705 
 706 
Main Secondary and Exploratory Endpoints: 707 
• Time to first occurrence of any of the following single events: 708 
o Major amputation of the index leg. 709 
o Revascularization due to worsening of CLI in the index leg. 710 
o Doubling of total ulcer area from baseline in the index leg. 711 
o De novo necrosis in the index leg. 712 
o All-cause mortality. 713 
• Time to major amputation of the index leg. 714 
• Complete healing of all ischemic lesions at 12 months. 715 
• Change from baseline in ischemic pain (Numerical rating scale (NRS)) at 6 months. 716 
• Time to death or major amputation or adjudicated major amputation of the index leg. 717 
• Time to all cause death. 718 
• Decrease of 50% or more in total ulcer area at 6 months. 719 
• Complete healing of all ischemic lesions in the contralateral leg. 720 
• Time to occurrence of major amputation of the contralateral leg. 721 
• Change in health- and disease-related Quality of Life at 12 months. 722 
• Changes in tcPO2, ankle-brachial index (ABI), toe-brachial index (TBI). 723 
• Revascularization procedure in the index leg within 12 months from treatment. 724 
• Hospitalization days. 725 
• Change from baseline in plasma cytokine levels after PLX-PAD administration. 726 
























Legends to figures 749 
 750 
Figure 1 751 
 752 
Suggested mechanism of PLX-PAD effect in CLI. PLX-PAD secretions can mitigate CLI 753 
pathology by simultaneously affecting several disease associated pathways. PLX-PAD secrete 754 
immunomodulatory cytokines which support the induction of M2 macrophages and elevate 755 
the level of circulating regulatory T cells,  leading to elevation in IL-10 and resolution of 756 
inflammation. In addition, PLX-PAD secrete factors which directly support angiogenesis and 757 
muscle regeneration. These processes are further supported by the PLX-PAD secretion of 758 
enzymes with antioxidant activity, which can protect blood vessels from oxidative damage, 759 
and the secretion of ECM (extracellular matrix) remodeling enzymes which enable 760 
regeneration.  761 
 762 
Figure 2  763 
 764 
PLX-PAD cells are effective in re-establishing blood flow in the HLI mouse model. 765 
Intramuscular (IM) administration to the ischemic or contralateral limb, were  effective in 766 
rescuing blood flow to the ischemic limb compared to placebo control. PLX-PAD were 767 
administered 1 and 21 days (depicted by arrows on graph) following induction of HLI. n=10 768 
for each PLX-PAD treated group and n=5 for placebo group. F(39,70)=30.82, p<0.0001. Blood 769 
flow is measured as perfusion ratio relative to the contralateral limb. *p<0.05; ***  770 
p < 0.0001, compared to placebo control. 771 
 772 
Figure 3 773 
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Figure 4 780 
 781 






















  802 
